We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GENIL:BISTGen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S. Analysis

Data as of 2026-08-16 - not real-time

TRY 10.93

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi is priced at TRY 10.93, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 19.2%. With RSI at 67.6 the momentum picture is approaching overbought, alongside a bullish MACD signal. Recent trading has carved out support near TRY 8.99 and resistance around TRY 11.83.
Multiples put this in overvalued territory: 47.5 times earnings against the sector's 29.8. Revenue is growing at 41.7% on a 5.1% profit margin. The 0.31% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 7 — elevated. With 30-day volatility of 42.1%, a beta of 0.11 and a maximum drawdown of 50.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.

Top Market Events

GEN ILAC VE SAGL 2026-03-01 tarihli - KAP bildirimleri Bloomberg HT'de!GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading above the 200-day average of 10.02
  • MACD momentum is positive
  • 30-day price change of +19.2%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 47.5 versus sector average of 29.8
  • Trading above the 200-day average of 10.02
  • 30-day volatility of 42.1%

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 47.5 versus sector average of 29.8
  • Revenue growth of +41.7%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth41.70%
Profit Margin5.07%
P/E Ratio47.5
ROE10.67%
ROA8.65%
Debt/Equity40.79
P/B Ratio3.8
Op. Cash FlowTRY1.5B
Free Cash FlowTRY-4289989120
Industry P/E29.8

Technical Analysis

TrendNeutral
RSI67.6
SupportTRY 8.99
ResistanceTRY 11.83
MA 20TRY 9.72
MA 50TRY 9.27
MA 200TRY 10.02
MACDBullish
VolumeIncreasing
Fear & Greed Index95.98

Valuation

Fair ValueTRY 6.92
GradeOvervalued
TypeGrowth
Dividend Yield0.31%

Risk Assessment

Beta0.11
Volatility42.08%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.